Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib
Paul B. Chapman, MD, from Memorial Sloan-Kettering Cancer Center, describes the most common side effects of the drug vemurafenib (Zelboraf), which includes rashes, joint pain, and inflammation of the liver. He describes that it is very important to be followed closely by a dermatologist while taking the drug because of the possible formation of non-melanoma skin tumors, squamous cell cancer of the skin, and other benign tumors that are easily excised if caught early.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making